Intensive Care Unit Management of Liver-Related Coagulation Disorders

Critical Care Clinics

Volumn 28, Issue 3, 2012, Pages 389-398

  Dasher, Kevin ^a   Trotter, James F ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Coagulopathy; International normalized ratio; Liver transplant; Thrombocytopenia

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE; DESMOPRESSIN; ELTROMBOPAG; FRESH FROZEN PLASMA; INTERFERON; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT ACTIVATED FACTOR VII; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM; THROMBOPOIETIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BLEEDING TIME; BLOOD CLOTTING DISORDER; CATARACT; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; END STAGE LIVER DISEASE; FULMINANT HEPATIC FAILURE; HEMOPHILIA; HEMOSTASIS; HEPATITIS C; HUMAN; HYPOFIBRINOGENEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; LIVER DYSFUNCTION; LUNG EMBOLISM; MYELODYSPLASTIC SYNDROME; PARTIAL THROMBOPLASTIN TIME; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL BLEEDING; VITAMIN K DEFICIENCY; VON WILLEBRAND DISEASE;

EID: 84862526210     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.04.006     Document Type: Review

References (60)

1. Bashour F.N., Teran J.C., Mullen K.D. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000, 95:2936-2939.
2. Aster R.H. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966, 45:645-657.
3. Stein S.F., Harker L.A. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982, 99:217-230.
4. Harker L.A., Finch C.A. Thrombokinetics in man. J Clin Invest 1969, 48:963-974.
5. Trotter J.F. Coagulation abnormalities in patients who have liver disease. Clin Liver Dis 2006, 10:665-678. x-xi.
6. Kinjo N., Kawanaka H., Akahoshi T., et al. Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension. Br J Surg 2010, 97:910-916.
7. Hayashi P.H., Mehia C., Joachim Reimers H., et al. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. J Clin Gastroenterol 2006, 40:740-744.
8. Kujovich J.L. Hemostatic defects in end stage liver disease. Crit Care Clin 2005, 21:563-587.
9. Bassendine M.F., Collins J.D., Stephenson J., et al. Platelet associated immunoglobulins in primary biliary cirrhosis: a cause of thrombocytopenia?. Gut 1985, 26:1074-1079.
10. Feistauer S.M., Penner E., Mayr W.R., et al. Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 1997, 25:1343-1345.
11. Pockros P.J., Duchini A., McMillan R., et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002, 97:2040-2045.
12. Ramos-Casals M., Garcia-Carrasco M., Lopez-Medrano F., et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003, 82:87-96.
13. Violi F., Leo R., Vezza E., et al. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol 1994, 20:531-536.
14. Escolar G., Cases A., Vinas M., et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999, 84:614-619.
15. Laffi G., Marra F., Gresele P., et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992, 103:641-646.
16. Laffi G., Marra F., Failli P., et al. Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993, 105:148-156.
17. Lisman T., Leebeek F.W. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007, 24:250-258.
18. Lisman T., Adelmeijer J., de Groot P.G., et al. No evidence for an intrinsic platelet defect in patients with liver cirrhosis-studies under flow conditions. J Thromb Haemost 2006, 4:2070-2072.
19. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005, 41:553-558.
20. Ben-Ari Z., Osman E., Hutton R.A., et al. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?. Am J Gastroenterol 1999, 94:2977-2982.
21. Mammen E.F. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992, 6:1247-1257.
22. Amitrano L., Guardascione M.A., Brancaccio V., et al. Coagulation disorders in liver disease. Semin Liver Dis 2002, 22:83-96.
23. Phillips J.R., Angulo P., Petterson T., et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001, 96:2745-2750.
24. Pereira S.P., Rowbotham D., Fitt S., et al. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol 2005, 42:365-370.
25. Kowdley K.V., Emond M.J., Sadowski J.A., et al. Plasma vitamin K1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol 1997, 92:2059-2061.
26. Caldwell S.H., Hoffman M., Lisman T., et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006, 44:1039-1046.
27. Sogaard K.K., Horvath-Puho E., Gronbaek H., et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009, 104:96-101.
28. Northup P.G., McMahon M.M., Ruhl A.P., et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006, 101:1524-1528. [quiz: 1680].
29. Tsochatzis E.A., Senzolo M., Germani G., et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010, 31:366-374.
30. Lisman T., Bongers T.N., Adelmeijer J., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006, 44:53-61.
31. Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001, 98:2730-2735.
32. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N Engl J Med 2011, 365:147-156.
33. Marwaha N., Sharma R.R. Consensus and controversies in platelet transfusion. Transfus Apher Sci 2009, 41:127-133.
34. Seeff L.B., Everson G.T., Morgan T.R., et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010, 8:877-883.
35. Malloy P.C., Grassi C.J., Kundu S., et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2009, 20:S240-S249.
36. Grabau C.M., Crago S.F., Hoff L.K., et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004, 40:484-488.
37. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357:2227-2236.
38. Eltrombopag to reduce the need for platelet transfusion in subjects with chronic liver disease and thrombocytopenia undergoing Elective Invasive Procedures (ELEVATE). GlaxoSmithKline Accessed April 18, 2012. http://www.clinicaltrials.gov/ct2/show/NCT00678587?term=NCT00678587%26rank=1.
39. Dultz G., Kronenberger B., Azizi A., et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011, 55:229-232.
40. Logan A.C., Yank V., Stafford R.S. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011, 154:516-522.
41. Bernstein D.E., Jeffers L., Erhardtsen E., et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997, 113:1930-1937.
42. Bosch J., Thabut D., Bendtsen F., et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004, 127:1123-1130.
43. Bosch J., Thabut D., Albillos A., et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008, 47:1604-1614.
44. Lodge J.P., Jonas S., Jones R.M., et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005, 11:973-979.
45. Levi M., Levy J.H., Andersen H.F., et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010, 363:1791-1800.
46. Abdel-Wahab O.I., Healy B., Dzik W.H. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006, 46:1279-1285.
47. Spector I., Corn M., Ticktin H.E. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease. N Engl J Med 1966, 275:1032-1037.
48. Williamson L.M., Llewelyn C.A., Fisher N.C., et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999, 39:1227-1234.
49. Youssef W.I., Salazar F., Dasarathy S., et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003, 98:1391-1394.
50. Burroughs A.K., Matthews K., Qadiri M., et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 1985, 291:1377-1381.
51. Wong A.Y., Irwin M.G., Hui T.W., et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003, 50:14-20.
52. de Franchis R., Arcidiacono P.G., Carpinelli L., et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 1993, 18:1102-1107.
53. Callum J.L., Karkouti K., Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009, 23:177-188.
54. Pereira S.P., Williams R. Adverse events associated with vitamin K1: results of a worldwide postmarketing surveillance programme. Pharmacoepidemiol Drug Saf 1998, 7:173-182.
55. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981, 26:388-393.
56. Dillon J.F., Simpson K.J., Hayes P.C. Liver biopsy bleeding time: an unpredictable event. J Gastroenterol Hepatol 1994, 9:269-271.
57. Boks A.L., Brommer E.J., Schalm S.W., et al. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986, 6:79-86.
58. Basili S., Ferro D., Leo R., et al. Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. J Hepatol 1996, 24:574-580.
59. Massicotte L., Beaulieu D., Thibeault L., et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation 2008, 85:956-962.
60. Lisman T., Leebeek F.W., Mosnier L.O., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001, 121:131-139.